False Claims Act Prosecution Did Not Deter Off-Label Drug Use In The Case Of Neurontin
Aaron S Kesselheim, Devan Darby, David M Studdert, Robert Glynn, Raisa Levin, Jerry Avorn
Health Affairs | PROJECT HOPE | Published : 2011
Awarded by Agency for Healthcare Research and Quality
Aaron Kesselheim is supported by a Career Development Award from the Agency for Healthcare Research and Quality (No. K08HS18465-01) and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research. Devan Darby was supported by a grant from the John D. Stoeckle Center for Primary Care Innovation at Massachusetts General Hospital. David Studdert is supported by a Federation Fellowship from the Australian Research Council.